391 related articles for article (PubMed ID: 29523629)
1.
Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
[TBL] [Abstract][Full Text] [Related]
2. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Van Binnebeek S; Baete K; Vanbilloen B; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Haustermans K; Van Cutsem E; Verbruggen A; Bogaerts K; Verslype C; Deroose CM
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1141-57. PubMed ID: 24668274
[TBL] [Abstract][Full Text] [Related]
3. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
6. A five-compartment biokinetic model for
Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
[TBL] [Abstract][Full Text] [Related]
7. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
8. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
9. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
Cremonesi M; Ferrari M; Zoboli S; Chinol M; Stabin MG; Orsi F; Maecke HR; Jermann E; Robertson C; Fiorenza M; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Aug; 26(8):877-86. PubMed ID: 10436201
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
Menda Y; O'Dorisio MS; Kao S; Khanna G; Michael S; Connolly M; Babich J; O'Dorisio T; Bushnell D; Madsen M
J Nucl Med; 2010 Oct; 51(10):1524-31. PubMed ID: 20847174
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
Hindorf C; Chittenden S; Causer L; Lewington VJ; Mäcke HR; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):130-5. PubMed ID: 17627421
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
13. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
16. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
18. [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
Stahl A; Schachoff S; Beer A; Winter A; Wester HJ; Scheidhauer K; Schwaiger M; Wolf I
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1328-36. PubMed ID: 16645839
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-Based Index and
Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
